These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9595061)

  • 1. Immunosuppression in the 21st century.
    Van Buren C
    Transplant Proc; 1998 May; 30(3):694-5. PubMed ID: 9595061
    [No Abstract]   [Full Text] [Related]  

  • 2. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
    Lin Y; Waer M
    Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
    [No Abstract]   [Full Text] [Related]  

  • 3. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy.
    Cohen DS; Fisher RA; Shapiro JH; Goggins WC; Tawes JW; Mills S; Contos M; Ham JM; Schroeder TJ
    Transplant Proc; 1996 Oct; 28(5):2501-5. PubMed ID: 8907923
    [No Abstract]   [Full Text] [Related]  

  • 4. Synergistic effect of 3M KCl-extracted donor antigens with cyclosporine or cyclosporine/rapamycin to prolong heart allograft survival in rats.
    Hamashima T; Stepkowski SM; Smith S; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3053-5. PubMed ID: 7940960
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic effect of rapamycin and cyclosporine in pancreaticoduodenal transplantation in the rat.
    Chen H; Wu J; Luo H; Daloze P
    Transplant Proc; 1992 Jun; 24(3):892-3. PubMed ID: 1604658
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined rapamycin and cyclosporine immunosuppression in a porcine renal transplant model.
    Granger DK; Cromwell JW; Canafax DM; Matas AJ
    Transplant Proc; 1996 Apr; 28(2):984. PubMed ID: 8623488
    [No Abstract]   [Full Text] [Related]  

  • 7. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow.
    Hale DA; Gottschalk R; Maki T; Monaco AP
    Transplantation; 1998 Feb; 65(4):473-9. PubMed ID: 9500619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple combination of cyclosporine, brequinar, and rapamycin prolongs kidney allograft survival in the mongrel dog.
    Ferraresso M; Knight R; Tu Y; Stepkowski SM; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3028. PubMed ID: 7940953
    [No Abstract]   [Full Text] [Related]  

  • 9. Perioperative immunosuppression as a critical determinant of early outcome after discordant xenoislet transplantation: a comparative study.
    Troppmann C; Papalois BE; Gruessner AC; Moon C; Matas AJ; Sehgal SN; Nakhleh RE; Gruessner RW
    Transplant Proc; 1996 Apr; 28(2):981-3. PubMed ID: 8623487
    [No Abstract]   [Full Text] [Related]  

  • 10. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival.
    Stepkowski SM; Wang M; Qu X; Yu J; Okamoto M; Tejpal N; Kahan BD
    Transplant Proc; 1998 Aug; 30(5):2214-6. PubMed ID: 9723445
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined effect of rapamycin and cyclosporine in the prevention of rat corneal allograft rejection.
    Thompson P; Xu D; Brunette I; Chen H
    Transplant Proc; 1998 Jun; 30(4):1033-5. PubMed ID: 9636417
    [No Abstract]   [Full Text] [Related]  

  • 12. Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice.
    Stepkowski SM; Tu Y; Chou TC; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3025-7. PubMed ID: 7940952
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
    Hale DA; Gottschalk R; Maki T; Monaco AP
    Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine.
    Hale DA; Gottschalk R; Wood ML; Maki T; Monaco AP
    Transplant Proc; 1996 Dec; 28(6):3270-1. PubMed ID: 8962270
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapamycin in a porcine renal transplant model.
    Almond PS; Moss A; Nakhleh R; Melin M; Chen S; Salazar A; Shirabe K; Matas A
    Transplant Proc; 1993 Feb; 25(1 Pt 1):716. PubMed ID: 8438452
    [No Abstract]   [Full Text] [Related]  

  • 16. Extended skin allo- and xenograft survival in mice treated with rapamycin, antilymphocyte serum, and donor-specific bone marrow transfusion.
    Hale DA; Gottschalk R; Fukuzaki T; Wood ML; Maki T; Monaco AP
    Transplant Proc; 1996 Dec; 28(6):3269. PubMed ID: 8962269
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival.
    Stepkowski SM; Kahan BD
    Transplant Proc; 1991 Dec; 23(6):3262-4. PubMed ID: 1750091
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of immunosuppression on chronic rejection in the rat aortic allograft model.
    Belitsky P; Gulanikar A; He G; Gupta R
    Transplant Proc; 1993 Feb; 25(1 Pt 2):935. PubMed ID: 8442272
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation.
    Markus PM; Cai X; Selvaggi G; Cooper M; Harnaha J; Fung JJ; Starzl TE
    Transplant Proc; 1991 Dec; 23(6):3232-3. PubMed ID: 1721418
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse.
    Chen H; Qi S; Xu D; Fitzsimmons WE; Bekersky I; Sehgal SN; Daloze P
    Transplant Proc; 1998 Sep; 30(6):2579-81. PubMed ID: 9745497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.